

CLAIMS

1. Use of a substance for synthesising a drug for the treatment of patients who
5 suffer from a pulmonary disease which is directly or indirectly associated to idiopathic pulmonary disease, hypersensitive pneumonia or diffused panbronchitis, wherein said substance is a peptide or a polypeptide containing the following amino acid sequence:
- 10 Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 1).
2. Use according to claim 1, wherein said peptide or a polypeptide further containing following amino acid sequence:
- 15 His-Ser-Asp (SEQ ID NO. 14); Phe-Thr-Asp (SEQ ID NO. 13).
3. Use according to claim 1, wherein said peptide or a polypeptide having following amino acid sequence:
- 20 $(A)_n$ -Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu- $(B)_m$
- wherein A, B is any natural amino acid, A and B are independent of each other; and n, m replacing values from 0-25; n and m are independent of each other.
- 25 4. Use according to claim 3, wherein $(A)_n$ has following sequence if $n > 2$:
 $(X)_o$ -Phe-Thr-Asp- $(Y)_p$;
wherein X, Y is any natural amino acid, X and Y are independently of each other; and o, p is a replacing value from 0-11, o and p are independent of each other.
- 30 5. Use according to claim 4, wherein $(X)_o$ has following sequence if $o > 2$:
 $(X')_q$ -His-Ser-Asp- $(X'')_r$,
wherein X', X'' is any natural amino acid, X' and X'' are independent of each other; and r, q is a replacing value from 0-4, r and q are independent of each other.
- 35 6. Use according to claim 3, wherein the sequence of said peptide or polypeptide belongs to following group:
(i) Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 4)

- (ii) Phe-Thr-Asp-X¹-X²-X³-X⁴-X⁵-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (SEQ ID NO. 5);
- (iii) Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (SEQ ID NO. 6);
- 5 (iv) Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 7);
- (v) His-Ser-Asp-X¹-X²-Phe-Thr-Asp-X³-X⁴-X⁵-X⁶-X⁷-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 9);
- (vi) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu (SEQ ID NO. 10);
- 10 (vii) His-Ser-Asp-X¹-X²-Phe-Thr-Asp-Asp-X³-X⁴-X⁵-X⁶-X⁷-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-X⁸-X⁹-X¹⁰-X¹¹-(X¹²) (SEQ ID NO. 11);
- (viii) His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn (VIP, SEQ ID NO. 1);
- 15 (ix) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu (PACAP-38, SEQ ID NO. 2);
- (x) His-Ser-Asp-X¹-X²-Phe-Thr-Asp-X³-X⁴-X⁵-X⁶-X⁷-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu X⁸-X⁹-X¹⁰-X¹¹-X¹²-X¹³-X¹⁴-X¹⁵-X¹⁶-X¹⁷-X¹⁸-X¹⁹-X²⁰-X²¹-X²² (SEQ ID NO. 12);
- 20 (xi) His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys (PACAP-27, SEQ ID NO. 3);

wherein X¹ - X²² is any naturally occurring amino acid.

- 25
7. Use according to claims 1 – 6, wherein any said peptide or polypeptide is an analogue or a derivative with the same biological function.
8. Use according to claim 7, wherein any said peptide or polypeptide is in a stabilised form.
- 30
9. Use according to claims 1-8, wherein said disease is idiopathic pulmonary fibrosis.
- 35
10. Use according to claims 1-8, wherein said disease is hypersensitive pneumonia.
11. Use according to claims 1-8, wherein said disease is diffused panbronchiolitis.

12. Use according to claims 1-8, wherein the therapeutically effective peptides are administered as aerosols.